Cargando…

An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB

Emerging Omicron sub-variants are causing global concerns, and their immune evasion should be monitored continuously. We previously evaluated the escape of Omicron BA.1, BA.1.1, BA.2, and BA.3 from an atlas of 50 monoclonal antibodies (mAbs), covering seven epitope classes of the severe acute respir...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Qingwen, Wu, Lili, Xu, Zepeng, Wang, Xiaoyun, Xie, Yufeng, Chai, Yan, Zheng, Anqi, Zhou, Jianjie, Qiao, Shitong, Huang, Min, Shang, Guijun, Zhao, Xin, Feng, Youjun, Qi, Jianxun, Gao, George Fu, Wang, Qihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027947/ https://www.ncbi.nlm.nih.gov/pubmed/37019110 http://dx.doi.org/10.1016/j.xcrm.2023.100991

Ejemplares similares

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
por: Zhang, Yanfang, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Striking antibody evasion of SARS-CoV-2 Omicron sub-lineages BQ.1.1, XBB.1 and CH.1.1
por: Ju, Bin, et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants
por: Popovic, Marko
Publicado: (2023)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
por: Ju, Bin, et al.
Publicado: (2023)

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
por: Wang, Qian, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
por: Bellusci, Lorenza, et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
por: Mykytyn, Anna Z, et al.
Publicado: (2023)

Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022
por: Vikse, Elisabeth Lea, et al.
Publicado: (2023)

Adaptability of single nucleotide polymorphism (SNP)-PCR for subtyping SARS-CoV-2 and a new SNP-PCR for XBB, XBB.1.5, and B.Q.1/B.Q.1.1
por: Ritchie, Gordon, et al.
Publicado: (2023)

Consensus insertion/deletions and amino acid variations of all coding and noncoding regions of the SARS-CoV-2 Omicron clades, including the XBB and BQ.1 lineages
por: Suharsono, Hamong, et al.
Publicado: (2023)

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2023)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
por: Amano, Masayuki, et al.
Publicado: (2023)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
por: Shah, Masaud, et al.
Publicado: (2023)

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
por: Bruel, Timothée, et al.
Publicado: (2023)

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
por: Entzminger, Kevin C, et al.
Publicado: (2023)

Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
por: Varghese, Ryan, et al.
Publicado: (2023)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
por: Zuo, Fanglei, et al.
Publicado: (2023)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
por: Qu, Panke, et al.
Publicado: (2023)

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
por: Qu, Panke, et al.
Publicado: (2023)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Emergence BQ.1 and BQ.1.1 as newly identified omicron subvariants: current scenario and future outlook – an update
por: Akash, Shopnil, et al.
Publicado: (2023)

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
por: Davis-Gardner, Meredith E., et al.
Publicado: (2022)

COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
por: Chen, Wei-Chun, et al.
Publicado: (2023)

What to know about Omicron XBB.1.5
por: Vogel, Lauren
Publicado: (2023)

Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273
por: Hernández, Jesús, et al.
Publicado: (2023)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB
por: Ding, Yuan, et al.
Publicado: (2023)

Coding-Complete Genome Sequences of 40 SARS-CoV-2 Omicron XBB, XBB.1, and XBB.2 Sublineage Strains in Bangladesh
por: Habib, Mohammad Tanbir, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_va9usljtugo24c3n7rqcf48orf